

Post Marketing Observational Study on Safety of BALFAXAR vs. KCENTRA for Reversal of Vitamin K Antagonist Induced Anticoagulation in Adults Undergoing Urgent Surgery or Invasive Procedure

NCT06429787

Status RECRUITING
Sponsor Octapharma
Enrollment 3,574 participants

Key Eligibility Criteria

Inclusion (3)

- Subjects at least 18 years of age.
- Subjects on VKA treatment.
- Received 4F-PCC agent, BALFAXAR or Kcentra, for urgent reversal of within 48 hours prior to urgent surgery or invasive procedure.

Exclusion (2)

- History of TEE within 90 days before receipt of VKA reversal therapy.
- Subjects treated with VKA reversal therapy and not undergoing urgent invasive procedure.

Locations (1 total)

Octapharma Research Site, Boston, Massachusetts, United States